Table 2

Tyrosine kinase and mTOR inhibitor target expression in primary and metastatic RCC samples
Target AQUA scores, primary specimens (mean ± SD) AQUA scores, metastatic specimens (mean ± SD) t-statistic p-value
B-Raf 32.1 ± 8.9 31.2 ± 10.2 −0.417 0.678
C-Raf 26.7 ± 2.1 28.4 ± 2.5 0.519 0.605
cKit 23.3 ± 1.3 23.4 ± 1.3 0.079 0.937
FGF-R1 29.1 ± 1.1 29.9 ± 0.9 0.579 0.564
HIF-2α 58.2 ± 1.9 58.2 ± 2.0 0.014 0.989
mTOR 18.8 ± 1.4 22.4 ± 1.8 1.637 0.106
PDGF-Rβ 24.7 ± 0.9 27.9 ± 1.5 1.879 0.064
VEGF-R1 22.6 ± 0.9 23.9 ± 1.2 0.34 0.735
VEGF-R2 36.5 ± 2.4 33.5 ± 1.7 −1.294 0.200
VEGF-R3 45.6 ± 2.0 46.5 ± 1.6 0.371 0.712
VEGF 24.7 ± 1.0 26.0 ± 1.1 0.907 0.367
VEGF-B 11.2 ± 0.6 11.8 ± 0.9 0.486 0.628
VEGF-C 17.0 ± 1.3 14.3 ± 1.2 −1.544 0.127
VEGF-D 35.0 ± 1.2 36.8 ± 1.3 1.018 0.312
MEK1 37.5 ± 2.5 50.3 ± 3.1 3.183 0.002
ERK1/2 17.0 ± 1.1 18.6 ± 1.7 0.802 0.425

Aziz et al.

Aziz et al. BMC Clinical Pathology 2013 13:3   doi:10.1186/1472-6890-13-3

Open Data